Inertia
Well-Known Member
I didn't add this to my CBD or Stock Market Thread in case those that can use this info may miss it in those threads.
Vertex Pharmaceuticals VRTX announced positive results from three late-stage studies on its investigational orally-administered non-opioid pain medicine, VX-548, to treat moderate-to-severe acute pain.
The company evaluated VX-548, a novel first-in-class NaV1.8 inhibitor, in two pivotal phase III acute pain studies — one following bunionectomy surgery and the other following abdominoplasty surgery. The studies achieved their primary endpoint — treatment with VX-548 showed a significant reduction in pain intensity across a 48-hour period compared with placebo.
Both studies failed to meet a key secondary goal of the superiority of VX-548 over the combination of opioid drug hydrocodone bitrate and acetaminophen (HB/APAP) in reducing pain.
Vertex also evaluated VX-548 for up to 14 days in a single-arm late-stage study across a broad range of other surgical and non-surgical acute pain conditions. Data from the study showed that around 83% of study participants rated the drug as ‘good, very good, or excellent’ in treating pain
ca.finance.yahoo.com
Hopefully soon to be avail for release.
Good luck
Vertex Pharmaceuticals VRTX announced positive results from three late-stage studies on its investigational orally-administered non-opioid pain medicine, VX-548, to treat moderate-to-severe acute pain.
The company evaluated VX-548, a novel first-in-class NaV1.8 inhibitor, in two pivotal phase III acute pain studies — one following bunionectomy surgery and the other following abdominoplasty surgery. The studies achieved their primary endpoint — treatment with VX-548 showed a significant reduction in pain intensity across a 48-hour period compared with placebo.
Both studies failed to meet a key secondary goal of the superiority of VX-548 over the combination of opioid drug hydrocodone bitrate and acetaminophen (HB/APAP) in reducing pain.
Vertex also evaluated VX-548 for up to 14 days in a single-arm late-stage study across a broad range of other surgical and non-surgical acute pain conditions. Data from the study showed that around 83% of study participants rated the drug as ‘good, very good, or excellent’ in treating pain
Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal
Three late-stage studies data show that Vertex's (VRTX) experimental non-opioid drug reduced pain across a 48-hour period. Based on this data, VRTX intends to submit an FDA filing by mid-2024.
Hopefully soon to be avail for release.
Good luck
